Edesa Biotech, Inc. (EDSA)

Over the past six months, Edesa Biotech's stock price has been impacted by several events. On October 28, 2025, positive Phase 3 respiratory study results were reported, but the stock saw a -17.87% movement. On October 31, 2025, the company announced its upcoming conference schedule, resulting in a -6.45% stock movement. On December 12, 2025, Fiscal Year 2025 results were reported, coinciding with a -16.09% stock price change. On February 13, 2026, Fiscal 1st Quarter 2026 results showed a slight positive movement of +0.49%. On February 24, 2026, shares surged by 67.96% after reporting additional positive results from its Phase 3 paridiprubart study. On March 26, 2026, advancements in its vitiligo program led to a -10.81% stock movement. SEC filings indicated open-market purchases of EDSA shares by CEO Pardeep Nijhawan and CEO-linked entities, as well as President Michael J. Brooks. A Schedule 13G filing indicated Perceptive Advisors' stake of 563,239 shares in EDESA.

The provided information does not contain specific details regarding demand seasonality for Edesa Biotech's products and services. As a clinical-stage biopharmaceutical company, its primary activities revolve around research, development, and clinical trials of drug candidates rather than the commercial sale of approved products. The demand for its potential future products would be driven by disease prevalence and treatment efficacy, rather than seasonal fluctuations.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, manufacturing, and commercializing pharmaceutical products for inflammatory and immune-related diseases. The company operates within the Medical sector, specifically the Biotechnology and Pharmaceutical Preparations industry, developing host-directed therapeutics that modulate the body's immune response. Its clinical pipeline is organized around Medical Dermatology and Respiratory diseases, with major product candidates including EB05 (paridiprubart) for ARDS, EB06 for vitiligo, EB01 (1.0% daniluromer cream) for chronic Allergic Contact Dermatitis, and EB07 for vitiligo and pulmonary fibrosis.

Edesa Biotech, Inc. is headquartered in Markham, Ontario, Canada, and maintains U.S. offices. Clinical trials have been conducted internationally and with U.S. government funding, but broader geographic marketing or operational footprints are not extensively disclosed.

Information specifically detailing Edesa Biotech's brand reputation in the past year is not readily available. The company's reputation is likely influenced by its clinical trial results and financial performance. Positive Phase 3 results for paridiprubart in ARDS would generally contribute positively to its scientific and clinical reputation. Negative stock movements following other announcements could be perceived negatively by investors. The company's focus on addressing unmet medical needs in immuno-inflammatory conditions also contributes to its public image.

Edesa Biotech, Inc. has 27 institutional owners and shareholders holding a total of 3,052,674 shares, including Rubric Capital Management LP, Stonepine Capital Management, LLC, Velan Capital Investment Management LP, Nantahala Capital Management, LLC, DRW Securities, LLC, Diadema Partners Lp, Citadel Advisors Llc, Geode Capital Management, Llc, Vanguard Group Inc, State Street Corp and Perceptive Advisors. Key individual owners and insiders include Dr. Pardeep Nijhawan, who beneficially owns approximately 19.99% of Edesa's outstanding common shares, and Michael J. Brooks, who directly owns 226,870 common shares.